Other languages Nova Mentis Life Science Corp.

Equities

NOVA

CA66980V1067

Market Closed - Canadian Securities Exchange Other stock markets 03:38:53 2024-04-25 pm EDT			5-day change	1st Jan Change
0.015 ^CAD	0.00%		+50.00%	-25.00%

Apr. 08	Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 26	Nova Mentis Life Science Corp. Announces the Appointment of Steve Loutskou to the Board of Directors	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08
Nova Mentis Life Science Corp. Announces the Appointment of Steve Loutskou to the Board of Directors	Feb. 26
Nova Mentis Life Science Corp. Announces Management Changes	Jan. 03
Nova Mentis Life Science Corp. Announces Resignation of Dr. Stephen Glazer as Chief Scientific Officer and Director	Dec. 11
Nova Mentis Life Science Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28
Nova Mentis Life Science Corp.: Nova Mentis begrüßt Entscheidung der Regierung zur Einrichtung einer Beratergruppe für seltene Krankheiten	Nov. 03
Nova Mentis Life Science Corp. Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome	23-08-29
Nova Mentis Life Science Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28
Nova Mentis Life Science Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30
Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25
Nova Mentis Life Science Corp. Auditor Raises 'Going Concern' Doubt	23-04-24
KGK Science Inc. Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial	23-04-18
KGK Sciences Inc. Begins Recruiting Participants, on Behalf of Client Nova Mentis Life Science Corp. in First-Ever Clinical Trial Investigating Effects of Psilocybin on Adults Diagnosed with Fragile X Syndrome	23-04-18
Nova Mentis Life Science Corp. Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial	23-04-11
Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial	23-02-14
Nova Mentis Life Science Corp. Announces Board Changes	23-01-18
Nova Mentis Receives Health Canada Approval for First-Of-its-Kind Psilocybin Clinical Trial	22-12-22
Nova Mentis Life Science Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24
Nova Mentis Enters into Research Services Contract with KGK Science for Phase II A Clinical Trial	22-11-17
Nova Mentis Life Science Corp. Produces 1.5 mg Psilocybin Microdose Capsules	22-09-29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Nova Mentis Life Science Corp.

Equities

NOVA

CA66980V1067

Other languages

Filters